Logo
x

Search

Subscribe Now

Mutations

Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval in Children Aged 6 to 11 with Certain Mutations in Cystic Fibrosis

Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval in Children Aged 6 to 11 with Ce...

  • June 10, 2021
Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations

Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations

  • March 16, 2021
Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations

Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Muta...

  • January 29, 2021
Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains

Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains

  • August 20, 2020
The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer

The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer

  • August 10, 2020
Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mutations in CFTR gene

Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mut...

  • November 2, 2018
Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC

    Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC

    • September 20, 2024
    Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cancer

      Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cance...

      • September 17, 2024
      Insights+: The US FDA New Drug Approvals in August 2024

        Insights+: The US FDA New Drug Approvals in August 2024

        • September 10, 2024
        Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

          Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

          • September 10, 2024
          Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

            Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

            • September 9, 2024
            Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma

              Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma

              • August 7, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.